Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

The weight of stress: Allostatic load as a predictor of vaso-occlusive episodes in adults with sickle cell disease

Marisol Miranda, Kellen Tjioe, Siera Gollan et al. Nov 03, 2025 pp. 1088-1088 10.1182/blood-2025-1088

Abstract Introduction: Sickle cell disease (SCD) is a debilitating hemoglobinopathy caused by a point mutation in the HBB gene, inducing hem...

Long-term follow up of nivolumab/ipilimumab-primed immunotransplant in patients with Relapsed/Refractory DLBCL

Graham Wehmeyer, Adam Kittai, Bailey Fitzgerald et al. Nov 03, 2025 pp. 2376-2376 10.1182/blood-2025-2376

Abstract Introduction: Patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) have poor outcomes, particularly those...

KP104, a bifunctional C5 mAb–Factor h fusion protein, demonstrates sustained long-term efficacy and safety in complement inhibitor–naïve PNH patients: 2-year results from A phase 2 study with 8-week post-treatment safety follow-up.

Li Zhang, Chen Yang, Changhe Yue et al. Nov 03, 2025 pp. 1118-1118 10.1182/blood-2025-1118

Abstract Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening hematologic disorder characterized by complement...

Safe: A multimodal, scalable and clinically-oriented comprehensive framework for synthetic data validation in hematology

Eleonora Iascone, Mattia Delleani, Gianluca Asti et al. Nov 03, 2025 pp. 396-396 10.1182/blood-2025-396

Abstract Background. The emergence of Generative AI is expanding the use of Synthetic Data (SD) for ground-breaking applications, such as di...

Trends and disparities in mortality from sideroblastic anemia and liver diseases in US adults (1999–2023): A CDC wonder analysis

Eshal Saghir, Mahtab Zafar, Muhammad Affan et al. Nov 03, 2025 pp. 6459-6459 10.1182/blood-2025-6459

Abstract Introduction: Sideroblastic anemia and liver diseases are clinically distinct but often interlinked through sim...

Integrative profiling of t-follicular helper cells heterogeneity and tumor microenvironment signatures in angioimmunoblastic T cell lymphoma

Tania Sainz, Vakul Mohanty, Yuchen Pan et al. Nov 03, 2025 pp. 555-555 10.1182/blood-2025-555

Abstract Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of mature T-cell lymphoma (TCL) that arises from T follicular helper (T...

Inverse association of legacy PFAS mixture exposure with neutrophil-to-lymphocyte ratio in United States adults: A survey-weighted analysis of the national health and nutrition examination survey (NHANES) 2005-2018

Woo Joo Lee, Seon Hye Won, Muhammad Sohaib Asghar et al. Nov 03, 2025 pp. 6552-6552 10.1182/blood-2025-6552

Abstract Background & Objective Per- and polyfluoroalkyl substances (PFAS) may alter immune function. We tested whether serum levels of...

Venetoclax and azacytidine in childhood primary advanced myelodysplastic syndromes, refractory/relapsed Acute Myeloid Leukemia and therapy-related myeloid diseases

Francesco Baccelli, Pietro Merli, Gennaro Pagano et al. Nov 03, 2025 pp. 289-289 10.1182/blood-2025-289

Abstract Introduction. Refractory or relapsed acute myeloid leukemia (r/r-AML), myelodysplastic syndromes with excess blasts (MDS-EB), and t...

A pre-admission chemotherapy checklist: Improving timeliness of chemotherapy initiation in a malignant hematology inpatient unit

Nina Dambrosio, Scott Heinemann, Erin Santavicca et al. Nov 03, 2025 pp. 6189-6189 10.1182/blood-2025-6189

Abstract Introduction In an elective admission, patients are admitted to the hospital on a scheduled day for chemotherap...

The whole brain radiotherapy is a safe and effective backbone in primary central nervous system lymphoma: A 23-year real-world experience

Haiyan Yang, Cong Li, Tao Lei et al. Nov 03, 2025 pp. 2752-2752 10.1182/blood-2025-2752

Abstract Background The current treatment management for primary central nervous system lymphoma (PCNSL) relies on high-dose methotrexate (H...

Cytoreductive therapy reduces recurrent thrombosis in patients with myeloproliferative neoplasm-associated splanchnic vein thrombosis: A global abdominal/splanchnic thrombosis retrospective observational study (GASTRO-MPN) study of 757 patients

Douglas Tremblay, Amica Ko, Pavlina Chrysafi et al. Nov 03, 2025 pp. 1026-1026 10.1182/blood-2025-1026

Abstract Background Patients with myeloproliferative neoplasms (MPNs) are at risk of splanchnic vein thrombosis (SVT). Prior studies failed...

Interim results of a quality improvement study evaluating subjective and objective sleep quality in hospitalized adults with acute leukemia

Michelle Zhang, Katie Russell, Madison Frieler et al. Nov 03, 2025 pp. 7956-7956 10.1182/blood-2025-7956

Abstract Background: Impaired sleep in hospitalized patients is associated with a myriad of adverse health outcomes. However, how sleep disr...

Improvement in kidney function after 12 months of voxelotor in sickle cell disease patients

Thomas Stehle, Vincent Audard, Edouard Reizine et al. Nov 03, 2025 pp. 2941-2941 10.1182/blood-2025-2941

Abstract Introduction: Sickle cell nephropathy (SCN) is characterized by glomerular and tubulointerstitial damage, as well as glomerular hyp...

Measuring success by different rulers: Heterogeneity in definition of outcomes in immune thrombocytopenia trials

Sofia Isabel Quezada Ramirez, Héctor Alejandro Vaquera Alfaro, José Emiliano Montelongo-Cepeda et al. Nov 03, 2025 pp. 3038-3038 10.1182/blood-2025-3038

Abstract Background: Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by low platelet coun...

Impact of obesity on inpatient outcomes in patients hospitalized with acute chest syndrome

Abdulmalek Aljafari, Adnan Humam Hajjar, Mayank Patel et al. Nov 03, 2025 pp. 4727-4727 10.1182/blood-2025-4727

Abstract Background: Acute chest syndrome (ACS) is a serious and potentially fatal complication of sickle cell disease. Obesity, a growing p...

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukemia in the chronic phase: Result of JALSG CML RE-STOP219 study.

Noriyoshi Iriyama, Naoto Takahashi, Katsumichi Fujimaki et al. Nov 03, 2025 pp. 5546-5546 10.1182/blood-2025-5546

Abstract Objective: In the management of chronic myeloid leukemia (CML), treatment-free remission (TFR) following tyrosine kinase inhibitor...

Clinical outcome of hematopoietic stem cell transplantation for juvenile myelomonocytic leukemia: A Single center in China

Sa Zong, Zhiyong Peng, Huaying Liu et al. Nov 03, 2025 pp. 4274-4274 10.1182/blood-2025-4274

Abstract Objective: To evaluate the safety and efficacy of hematopoietic stem cell transplantation (HSCT) in the treatment of juvenile myelo...

Investigating suspected germline STAG2 variants in myeloid neoplasms

Eno-obong Udoh, Yi Chen, Matteo D'Addona et al. Nov 03, 2025 pp. 5609-5609 10.1182/blood-2025-5609

Abstract BACKGROUND: Among cohesin complex genes, STAG2 is the most frequently mutated, prognostically unfavorable gene in high-risk MDS and...

Bridging the gap: Evaluating the impact of satellite clinics on CAR-T therapy access in the rural Southeast

Saranya Gourisetti, Anvi Peddi, Priyanka Menon et al. Nov 03, 2025 pp. 7931-7931 10.1182/blood-2025-7931

Abstract Background: Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment of relapsed or refra...

A prospective, single site, single-arm pilot study of CPX-351 (Vyxeos) in individuals <22 years with secondary myeloid neoplasms

Alyssa Kennedy, Yonghui Ni, Stanley Pounds et al. Nov 03, 2025 pp. 2097-2097 10.1182/blood-2025-2097

Abstract Background and Significance: Secondary myeloid neoplasms (SMN) in children and adolescents are rare malignancies with dismal progno...

Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic gvhd treatment: Multicenter retrospective analysis of a large german-austrian cohort of the belumosudil managed-access program.

Udo Holtick, Elisa Sala, Katharina Egger-Heidrich et al. Nov 03, 2025 pp. 6011-6011 10.1182/blood-2025-6011

Abstract Background: Chronic GvHD (cGvHD) is the most significant risk factor for late morbidity and mortality after allogeneic stem cell tr...

Prevalence and risk of aortic aneurysms in JAK2-positive myeloproliferative neoplasms: A multi-study review

Mohamad Dulli, Abdulrahman Al-Mashdali, Afra Ahmed et al. Nov 03, 2025 pp. 7349-7349 10.1182/blood-2025-7349

Abstract Background: Myeloproliferative neoplasms (MPNs) harboring JAK2 mutations, particularly V617F, have been increasingly linked with va...

Quality of life reporting in randomized trials for indolent lymphomas: A systematic review by sponsor type

Thomas Palladino, Charmi Trivedi, Sai Pranav Kota et al. Nov 03, 2025 pp. 7124-7124 10.1182/blood-2025-7124

Abstract Background: Indolent lymphomas are incurable malignancies with extended disease courses and prolonged overall survival (OS). This l...

Health-related quality of life with belantamab mafodotin in patients with relapsed or refractory multiple myeloma (RRMM): An exploratory analysis of overall quality of life in dreamm-7

Sagar Lonial, Craig Cole, Angely Loubert et al. Nov 03, 2025 pp. 4029-4029 10.1182/blood-2025-4029

Abstract Introduction: Belantamab mafodotin (belamaf) is an antibody-drug conjugate targeting B-cell maturation antigen. In DREAMM-7 (NCT0424...

Outcomes of patients with light-chain amyloidosis after heart transplantation: A single center cohort.

Jose Miguel Mateos Perez, Carlos Fernandez de Larrea, José Tomás Ortiz et al. Nov 03, 2025 pp. 7494-7494 10.1182/blood-2025-7494

Abstract INTRODUCTION: Systemic light chain (AL) amyloidosis is a plasma cell disorder characterized by the production of amyloidogenic mono...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page